Mass; Chicago, Ill; Denver and Aurora, Colo; and Albuquerque, NM Background: Overweight/obesity (OW) is linked to worse asthma and poorer inhaled corticosteroid (ICS) response in older children and adults. Objective: We sought to describe the relationships between OW and asthma severity and response to ICS in preschool children. Methods: This post hoc study of 3 large multicenter trials involving 2-to 5-year-old children compared annualized asthma symptom days and exacerbations among normal weight (NW) (body mass index: 10th-84th percentiles) versus OW (body mass index: > _85th percentile) participants. Participants had been
exacerbations (daily ICS: 0.6 vs 0.8, P 5 .10; short-term ICS: 1.1 vs 0.8 days, P 5 .25; as-needed ICS: 1.0 vs 1.1, P 5 .72). Compared with placebo, daily ICS in OW led to fewer annualized asthma symptom days (90.7 vs 41.2, P 5 .004) and exacerbations (1.4 vs 0.6, P 5 .006), while similar protective ICS effects were less apparent among NW. Conclusions: In preschool children off controller therapy, OW is associated with greater asthma impairment and exacerbations. However, unlike older asthmatic patients, OW preschool children do not demonstrate reduced responsiveness to ICS therapy. (J Allergy Clin Immunol 2018;141:1459-67.)
Key words: Asthma, overweight, obesity, children, infants, exacerbation Asthma is one of the most common chronic diseases of childhood and adolescence. 1, 2 High body mass index (BMI) status has a poorly defined relationship with asthma severity. According to national asthma guidelines, classification of asthma severity in controller-naive patients depends on impairment of daily functioning by asthma symptoms and risk of exacerbations. 3 Studies involving older youths and adults have found that overweight or obesity status (OW) worsens asthma symptoms, [4] [5] [6] asthma-related health care utilization, [6] [7] [8] and response to inhaled corticosteroids (ICS). [9] [10] [11] For example, Quinto et al 6 studied 32,321 children 5 to 17 years of age within the Kaiser Permanente health system and found that OW was associated with poor asthma control and exacerbations, measured by rescue inhaler and oral steroid dispensing, respectively. However, others have found no association between OW and measures of asthma severity, [12] [13] [14] or found that high BMI was associated with reduced (not greater) airway hyperresponsiveness, a central component of asthma. [15] [16] [17] It is possible that asthma in childhood may act in the opposite direction by promoting weight gain. 18 Very little data currently exist exploring the effects of OW status on asthma severity in preschool children. In addition, no studies to our knowledge have investigated OW and ICS response in preschoolers. The lack of research of OW status in preschoolers is an important gap in children's health considering that preschool children (<5 years of age) are at a particularly high risk for morbidity stemming from asthma or recurrent wheezing. Onehalf of all children experience wheezing by age 5 years 19 ; roughly one-third of preschool children suffer prolonged episodes of recurrent asthma symptoms 20 ; and among preschoolers, asthma symptoms are a leading cause of hospitalizations and emergency department visits. Additionally, the current prevalence of OW in the United States for 2-to 5-year-olds is 27%. 21 Elucidating the factors in preschool children that affect the treatment efficacy of ICS is of particular public health interest. If early life OW status does worsen asthma symptoms and reduces the effectiveness of ICS, early life nutrition and obesity prevention efforts could be intensified and become a critically important intervention.
Currently, ICS are the most effective single antiasthma controller medication available for the prevention of daily symptoms and exacerbations. Therefore, response to daily ICS is an important phenotypic characteristic of childhood asthma. Only a few studies in adults and 1 study in older children 11 have evaluated the effect of OW on ICS treatment response. Studies have demonstrated a reduced response to ICS among adults with high BMI. 9, 22, 23 In the Childhood Asthma Management
Program (CAMP) study, Forno et al 11 found that OW children, compared with normal weight (NW) children, demonstrated a reduced improvement in lung function and asthma-related urgent care use in response to ICS. Using data from 3 large prospective trials of preschool children enrolled in the Childhood Asthma Research and Education (CARE) and AsthmaNet networks, we evaluated the effects of early life OW status on prospectively determined asthma symptom days (AD) and exacerbations in children treated with either ICS (daily or intermittent step up) or placebo. We hypothesized that among both placebo-treated and ICS-treated children, OW status would lead to greater AD and exacerbations. [24] [25] [26] [27] All caregivers of participants signed written informed consents. The present post hoc study was approved by the Nemours Institutional Review Board (928923-2). We included baseline and intervention period data from 736 preschool-age participants (24-59 months) with mild persistent asthma or recurrent wheezing who were randomized into 1 of 3 multicenter placebo-controlled trials in which they received daily ICS, intermittent ICS, or placebo (see Table E1 in this article's Online Repository at www. jacionline.org for detailed entry criteria). Weights were determined using a calibrated electronic or beam balance scale. Standing height was measured without shoes using a calibrated stadiometer accurate to the nearest millimeter. Age-and sex-adjusted BMI percentiles were calculated using a centralized calculator using Centers for Disease Control and Prevention growth chart data. Because underweight children have also demonstrated more severe asthma, 28 participants with BMI <10th percentile were excluded in this analysis (see Table E2 in this article's Online Repository at www.jacionline.org).
METHODS

Participant selection
The INFANT study was a multicenter, randomized, double-blind, doubledummy, clinical trial in children 12 to 59 months (n 5 300) with persistent asthma, which was factorially linked to the Acetaminophen versus Ibuprofen in Young Children with Asthma (AVICA) study. Because treatment with ibuprofen compared with acetaminophen did not affect asthma outcomes, 29 we included INFANT data in the combined analysis. INFANT participants completed a 2-to 8-week run-in period followed by 3 16-week crossover intervention periods with daily ICS (fluticasone propionate, 88 mg twice daily; GlaxoSmithKline, Brentford, UK), daily leukotriene receptor antagonist (montelukast, 4 mg by mouth; Merck, Whitehouse Station, NJ), and intermittent ''as-needed'' ICS treatment (fluticasone propionate, 88 mg given whenever 2 inhalations of albuterol sulfate are needed; GlaxoSmithKline). The PEAK study was a multicenter double-blind 2-arm parallel study that randomly assigned 285 participants 2 to 3 years of age with a positive modified asthma predictive index to treatment with either fluticasone propionate (Glaxo SmithKline) 88 mg twice daily or masked placebo for 24 months. The MIST trial was a multicenter, randomized, double-blind, parallel trial that studied 278 children between the ages of 12 and 53 months who had recurrent wheezing and a positive modified asthma predictive index. Participants were randomly assigned to receive a budesonide inhalation suspension (Pulmicort Respules, AstraZeneca, Cambridge, UK) for 12 months as either a daily low-dose ICS (0.5 mg nightly) or an intermittent ''short-term'' ICS (1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness).
Clinical data
We analyzed demographics, medical, and environmental histories and asthma-related utilization among 736 participants from the 3 trials who were older than 24 months at enrollment. Intervention period data were collected over a 14-year period (PEAK 2001 (PEAK -2004 MIST 2008 MIST -2010 INFANT 2013 INFANT -2015 . Participants were classified as NW (10th-84th percentiles BMI) or OW (> _85th percentile BMI) based on BMI percentiles according to the Centers for Disease Control and Prevention classification. 30 Figures show AD and exacerbations by quartiles to demonstrate the lack of a BMI percentile trend and to justify combining percentiles 10 to 84 into 1 group. Aeroallergen testing was performed by skin prick test or blood ImmunoCAP (Phadia AB, Uppsala, Sweden) allergen-specific IgE.
During the intervention period, the impairment domain of asthma severity was measured by annualized AD. AD in the 3 studies were defined as days that included any daytime or nighttime asthmalike symptoms (cough, wheezing, nighttime awakening), unscheduled medical visits for respiratory symptoms, or use of any rescue asthma medications. AD were reported by caregivers using study-specific means including twice monthly interviews (PEAK), daily diary cards (MIST), and daily electronic home diaries (INFANT). Annualized rates of AD were determined for each participant.
Risk domain of asthma severity was measured by annualized asthma exacerbations. Exacerbations were defined similarly among the studies as events involving an increase in asthma symptoms requiring treatment with systemic corticosteroids to avoid serious worsening of asthma. Study staff blinded to treatment assignment diagnosed exacerbations of asthma based on conventional criteria including symptoms not responding to short-acting b-2 -agonists (SABA), frequent SABA use, prolonged moderate-severe symptoms, and physician discretion. 24, 26, 27 If caregivers sought care outside of the study staff that resulted in a diagnosis of an asthma exacerbation requiring systemic steroids, the event was considered an exacerbation.
Statistical analysis
Baseline data were summarized by study and by BMI group (Tables I and II ) . The primary analyses were comparisons between NW and OW in AD and exacerbations. The chi-square and Student t test (or Wilcoxon rank-sum test, as appropriate) were used for comparing categorical and continuous variables between 2 BMI groups, respectively. Multivariable generalized linear regression under the negative binomial likelihood was used to compare main outcomes between BMI groups and study treatments with race and ethnicity as additional covariates. For analyses combining multiple studies, study was also included as a covariate. The effect of BMI status on response to ICS was determined by including an interaction between BMI group and study treatment. To demonstrate the appropriateness of collapsing all children within the BMI range 10th to 84th percentiles and comparing NW versus OW, we presented annualized AD and exacerbations across 4 BMI-percentile groups. SAS, version 9.3 (SAS Institute, Cary, NC) was used. All tests were 2-tailed at a level of significance of .05.
RESULTS
Baseline characteristics
The baseline characteristics at randomization for 736 preschool children with asthma are shown by study and treatment in Table I . Baseline characteristics were similar across studies, and each individual study had regional and racial/ethnic diversity. Participants generally had mild-moderate asthma symptoms, were more likely to be male (271 of 736, 63%), and typically were diagnosed with asthma prior to 2 years of age. OW status affected 33% (244 of 736) of participants at baseline. A substantial portion of children were exposed to environmental tobacco smoke (291 of 736, 40%) and 1 or more pets in the home (334 of 736, 45%). More than one-half (404/of 736, 55%) displayed sensitization to 1 or more aeroallergens. On average, participants reported 1 to 2 asthma symptom days/week, while 64% (471 of/736) reported urgent care/emergency department use in the previous year for asthma.
OW status and asthma characteristics Table II shows asthma characteristics at randomization for the 736 participants by OW status. The OW group had a slightly lower prevalence of white and higher prevalence of Hispanic children. Reported home exposures to pets and tobacco smoke and objectively measured aeroallergen sensitization were similar between BMI groups. OW children had a significantly lower percentage of blood eosinophils. BMI status was not related to reported baseline symptom-free days, rescue SABA use, or recent urgent care. OW children had 63% higher odds of a reported hospitalization in the previous 12 months prior to enrollment (odds ratio: 1.63, 95% CI: 1.07-2.48).
Asthma severity during daily and step-up ICS treatment
In the 3 studies, a total of 485 children were randomized to an ICS intervention, either as daily treatment or as 1 of 2 strategies of intermittent ICS treatment. We found no evidence of OW status affecting annualized asthma symptom days while on daily ICS or either of the 2 intermittent ICS treatments (see Table III , Fig 1) . OW also did not affect the rate of exacerbation while on either of the 2 intermittent ICS strategies (Fig 2) . In the combined analysis of all 3 studies, OW children given daily ICS did not have a significantly different rate of exacerbations. An association between OW and exacerbations was noted only in the MIST study (see Table III , Fig 2, B) , while in the INFANT and PEAK studies OW participants treated with daily ICS experienced similar rates of exacerbations (Fig 2, A and C) .
Interaction of OW status and treatment with daily ICS
The PEAK trial was the only study that included both ICStreated and placebo-treated participants in the same trial. Participants in the PEAK trial (n 5 269) received either daily ICS or placebo for 2 years and are shown according to OW status (Table IV, Fig 3) . Among children given placebo (n 5 137), OW status, compared with NW status, was associated with significantly more AD and exacerbations (Table IV) . Placebo-treated OW children, compared with NW children, suffered 70% more AD (nearly 40 additional symptom days per year) and 75% more exacerbations. However, when similar children were randomized to daily ICS, the deleterious effects of OW status on AD and exacerbations were not observed. Only OW children displayed a significant ICS-related improvement in AD (P 5 .004) and exacerbations (P 5 .006). The treatment*OW status interaction P value approached but did not reach statistical significance for AD (P 5 .065) or prednisone courses (P 5 .13).
DISCUSSION
Among preschool children with a past history of asthma symptoms who are not on a daily controller, OW status is associated with significantly more AD and exacerbations. OW status at baseline was associated with greater likelihood of recent hospitalization for asthma despite similar exposure to tobacco smoke and pets in the home and reduced blood eosinophils. However, when OW and NW children were treated with ICS (daily, intermittent step up, or as-needed), their AD and exacerbations were similar. The weight effect with daily ICS To our knowledge, this is the first study to examine the effect of high BMI on asthma severity and ICS response in preschool-age Box plots represent medians and interquartile ranges. Whiskers represent 95% confidence ranges and points denote outliers. BMI percentile grouping did not affect AD, P values were > .05, which is nonsignificant (NS) for all panels A to E comparing BMI percentiles 10th-84th versus 85th-100th.
children. Strengths of the current study include that it involved a large number of preschoolers from 3 highly controlled trials with documented drug adherence and extensive phenotyping. The 3 trials were conducted prospectively by experienced pediatric asthma centers participating in 2 consecutive National Institutes of Health-funded research networks, and they recruited participants from diverse backgrounds from around the United States. The 3 trials had similar inclusion/exclusion criteria, which allowed consolidation of data for an individual patient-level data meta-analysis 31 (see Table E1 ). Monitoring of asthma severity in the preschool age is challenging and relies mainly on clinical markers of airway disease and in most children does not incorporate measures of airway responsiveness or airway inflammation. The current recommendations for assessing asthma control in this young age group involve daily monitoring for frequency and severity of symptoms and their impact on functioning, which describes the impairment domain of asthma control. Preschool children are most impacted by episodic severe exacerbations of symptoms, which often result in systemic steroid treatment and urgent care visits. The risk of asthma exacerbations corresponds to the risk domain of asthma control and is particularly important to the care of preschool children. Past studies that have attempted to evaluate the effect of high BMI in preschool children on asthma severity have been very few in number and have not utilized data from rigorously controlled trials with precise outcomes. For example, Aragona et al 32 conducted a retrospective cohort study using billing system and chart review data of hospitalized patients in the United States. Among children <5 years of age, OW children had greater than twice the odds of a repeat emergency department visit for asthma following discharge, while OW status exerted no effect in all other outcomes related to asthma including length of intensive care and hospital stay, total health care charges, and repeat admission. This retrospective analysis was limited by the fact that it assessed length of stay resulting from all treatments occurring during hospitalization, and OW effects were studied only among a subset of preschoolers (ie, those requiring hospitalization). Silveira et al 33 conducted a case-control study in 2 Brazilian teaching hospitals involving 3-to 12-year-olds, where case subjects and control subjects were children with persistent asthma and intermittent asthma, respectively. The study did not stratify by age and found that obesity was associated with higher odds of persistent (versus intermittent) asthma. Both of these studies report some association between high BMI and surrogates of asthma severity; however, both studies were modest in size and measurement bias and confounding from socioeconomic factors likely had some effect influence. The current study is the first to our knowledge to apply prospectively collected outcomes of both impairment and risk domains to assess the effect of body habitus on asthma severity. OW children in the current study not on daily ICS had nearly double the AD (roughly 0.5-1.3 excess AD per week, or 22-63 excess AD per year) and more than double the average annual exacerbations compared with those of NW children, which equates to a difference that is clinically meaningful.
ICS are clearly efficacious versus placebo in the control and prevention of asthma symptoms for most preschool children. [34] [35] [36] [37] In fact, ICS appears to be the most efficacious single therapy for the prevention of asthma symptoms in school-age children [38] [39] [40] [41] and preschoolers. 27, 42 However, poor response to ICS among preschoolers and school-age children remains a problem as evidenced by the high frequency of breakthrough exacerbations in ICS-treated preschoolers and the high degree of differential response in older children. 43, 44 Pooled data suggest that among preschool children the percentage of ICS responders may be as low as 40%. 45, 46 Establishing markers in preschool children that predict response to ICS would be a marked advance in clinical care. Current predictors of more favorable ICS response in the PEAK trial included male sex, white race, presence of atopy, and recent asthma-related emergency department use. 47 Predictors in older patients have included albuterol reversibility, reduced baseline lung function, 48 elevated exhaled nitric oxide, and bronchial reactivity by methacholine challenge. 49 Several studies in adults have reported that ICS is less effective in obese patients measured as AD, 23 rescue use, 9 lung function, 9,50 and exacerbations. 50 The mechanisms underlying these reduced treatment responses in the obese are unclear, but they may be related to greater neutrophilic airway inflammation in OW subjects, 51, 52 which has been associated with poor ICS response. 53 Additionally, OW status may also cause impaired apoptotic airway cell clearance (efferocytosis), which is key to resolving inflammation and airway health. 54 Based on our findings, in preschool children, these mechanisms do not appear to be leading to reduced ICS efficacy. High BMI in preschoolers in our analysis was associated with robust steroid responsiveness, which may be explained in part by the worse asthma severity at baseline.
Preschoolers in this study were treated with 3 possible ICS regimens (once daily, intermittent step up, and intermittent short- term). Each analysis evaluated the effect of OW on both AD and exacerbations. Among the resulting 6 analyses, OW was associated with worse ICS responses in just 1 (MIST daily ICS on exacerbations). Among the PEAK analysis, which had the longest observation period, daily ICS significantly improved both exacerbations and AD among OW preschoolers compared with OW preschoolers treated with placebo, while a similar improvement over placebo was not seen in NW preschoolers. We conclude that overall OW preschool children display a robust response to ICS, unlike what has been reported in older OW children and adults. Though more research is needed to refine the optimal ICS strategy in this age group (daily vs different intermittent approaches), the mainstay for symptomatic preschool children with asthma or recurrent wheezing at high risk for asthma has been the use of ICS, which we propose should remain the case in OW preschoolers.
The current study has several limitations, including its post hoc nature. Post hoc analyses are important for the generation of scientific hypotheses, but they should be regarded cautiously until findings can be replicated. However, the hypothesis and analytic approach of the current study was proposed a priori (before data was released for analysis). Since the study was not specifically powered to analyze OW-related effects, it is possible that a larger analysis could demonstrate different results. We chose the most common convention for defining pediatric OW (ie, BMI>85th percentile); however, high BMI percentile is only a marker for adiposity and can become elevated, particularly in shorter or muscular children, though this is probably less of a concern in preschool children than in older children and adults. Since this analysis did not follow BMI percentile over several years and did not involve a nonasthmatic comparison group, we are only able to assess phenotypic (impairment, risk) associations with OW among asthmatics. Though we did make statistical adjustments for differences between OW and NW children in race and ethnicity, we did not measure specific markers of socioeconomics (such as income or health literacy), which could be a confounding third factor associated with OW. In addition, our analysis was limited by the fact that we combined data from 3 studies with slightly different inclusion criteria and outcomes, including the method parents used to report AD and exacerbations (paper vs electronic diaries). It is possible that the associations reported between OW status and asthma outcomes are confounded by an unmeasured variable causally associated with OW and the asthma characteristics found in our analysis. Possibly related to this, we were limited to analyzing outcomes that were measured similarly (AD, exacerbations) in all 3 studies, and we did not analyze lung function. We chose to analyze only the children who were 12 to 59 months of age at enrollment to account for the slightly different ages across studies. Lastly, we did not attempt to adjust for possible variations in adherence.
In conclusion, early life high BMI does appear to worsen both impairment and risk domains of asthma severity in preschool children off controller therapy. Interventions that reduce early life weight gain and OW status may benefit respiratory health in preschool children. Future study of interventions aimed at reducing adiposity deserves to be done. OW status was not clearly associated with reduced response to ICS. Overall, preschool children in the 3 trials responded well to ICS, measured by daily asthma symptoms and, to a lesser extent, exacerbations, and thus ICS should remain the first-line treatment option for this high morbidity group.
Key message
d OW status is a risk factor in preschoolers for greater asthma impairment and exacerbations. 
